HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme
Articolo
Data di Pubblicazione:
2010
Tipologia CRIS:
1.1.2. Articolo in Rivista - Letter, Note
Keywords:
Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Immunosuppression; Male; Middle Aged; Pyridazines; Pyrrolidinones; RNA, Viral; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; 2708; Public Health, Environmental and Occupational Health; Pharmacology (medical); Infectious Diseases
Elenco autori:
Florence, E.; De Wit, S.; Castagna, Antonella; Ribera, E.; Hill, A.; Vanaken, H.; Van Delft, Y.; Marks, S.
Link alla scheda completa:
Pubblicato in: